List of major hepatitis B vaccine concept stocks
Guangzhou Pharmaceutical (600332) therapeutic hepatitis B DNA vaccine.
Fu Rui Co., Ltd. (300049) digital diagnosis of liver disease and liver fibrosis.
Connba (600572), a new drug developed for this product, has obtained a new drug clinical research approval, and the indication is hepatitis B virus treatment of sexual hepatitis.
Boya Biotechnology (300294) invested 87.5079 million yuan in the "Hepatitis B Human Immunoglobulin and Other Series Specific Immunoglobulin Industrialization Project". The construction period is one year. After the project is fully completed, it will process annual hepatitis B immunoglobulin production. 70.9 tons of plasma, and 980,000 bottles of hepatitis B human immunoglobulin are produced every year.
Shuanglu Pharmaceutical (002038) Xinxiang Shuanglu Biotechnology Co., Ltd. mainly produces products for the treatment of hepatitis B, tumors and cardiovascular diseases, etc. It is also engaged in biotechnology research, consulting and services and other related businesses.
Jiuzhitang (000989) hepatitis series drugs Yi Henan Ning Granules, Nuhua Zizhu Tablets, Xiaoyao Pills, Chidan Tuihuang Granules enjoy national confidential formula protection, Gastrodia Gouteng Granules, etc.
Chongqing Beer (600132) subsidiary Jiachen Biology and the People's Liberation Army's Third Military Medical University*** jointly developed a "therapeutic (synthetic peptide) hepatitis B vaccine.
Hengrui Medicine (600276) and the American CHEMEXHTERAPEUTICS company, INC Jointly developed a new nucleic acid-based highly effective anti-hepatitis B virus drug.
Guizhou Bailing (002424) hepatitis B drug. The anti-hepatitis B virus activity of Y101 has been confirmed many times by the 302 Hospital of the People's Liberation Army and the Institute of Pharmaceutical Biotechnology of the Chinese Academy of Medical Sciences; The effect of Y101 on liver protection, enzyme reduction, choleretic and anti-jaundice was further confirmed; the study found that the anti-hepatitis B virus mechanism of Y101 may be related to its CCCNDA inhibition of hepatitis B virus; preliminary experiments found that Y101 has the effect of fighting drug-resistant strains of hepatitis B virus. < /p>
Hualan Biological (002007) hepatitis B vaccine has obtained a new drug certificate, and the influenza vaccine has entered the trial production stage. In addition, multiple products have entered the clinical or approval stage. The company has cultivated the company through the construction of vaccine and vaccine projects. New profit growth points.
The viral vaccines jointly developed by Zhifei Biotechnology (300122) mainly include hand, foot and mouth disease vaccine, mixed hepatitis B therapeutic vaccine, and basic experimental research on therapeutic hepatitis B vaccine. 7 new tuberculosis vaccines, etc.
Watson Biotech (300142) began to develop recombinant (Hansenula yeast) hepatitis B vaccine (CPG adjuvant) in 2005, and applied for clinical approval in July 2009. In February 2011, the two specifications of the vaccine, 10 micrograms and 20 micrograms, have obtained approval from the State Food and Drug Administration for drug clinical trials. The drug still needs to undergo clinical research before the product can be put into production and marketed. During this period, technical and administrative approvals will be obtained. The time is uncertain.